UNSPSC 51142535: Phenglutarimide

This classification denotes an anticholinergic agent with the molecular formula C17H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 679RC9H8TG, chemically known as 2,6-piperidinedione, 3-(2-(diethylamino)ethyl)-3-phenyl- but generally known as phenglutarimide, which bears US NIH Compound Identifier 92870. European Medicines Agency schedules Phenglutarimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09762MIG. The term PHENGLUTARIMIDE is an International Non-Proprietary Name.

UNSPSC 51142535 Phenglutarimide is a Commodity code with minimal recent state and local procurement activity directly aligned to the code's nominal scope. The recent opportunities posted against this code show no actual demand for phenglutarimide itself; instead, Seminole County, Florida solicited naloxone and drug deactivation systems, while the Texas Health and Human Services Commission issued a market-intelligence request about direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) established a broad cooperative contract vehicle for generic multi-source pharmaceuticals and over-the-counter products. None of these procurements target phenglutarimide specifically, suggesting either a data-classification mismatch or dormant demand under this particular code at the state and local level.

The three recent solicitations span different issuing bodies—a county health department, a state health and human services agency, and a multistate cooperative purchasing alliance—and collectively indicate that state and local governments are buying pharmaceutical products, drug-safety equipment, and access to generic drug supply chains through wholesaler networks rather than individual chemical compounds. The Seminole County IFB (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI (posted April 3, 2026) explored vendor capacity for direct-to-manufacturer prescription fulfillment; and the MMCAP RFP (posted January 20, 2026, due March 26, 2026) structured a cooperative contract for generic pharmaceuticals and OTC products effective July 1, 2026, with pricing and competitiveness driving evaluation (75 percent weight). Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multistate structure extending to Oregon. The code shows little actionable recent demand for phenglutarimide itself and warrants close monitoring for misclassified opportunities or category-reassignment signals.